作者: William J. Hogan , Hans Joachim Deeg
DOI: 10.1385/1-59259-862-5:421
关键词:
摘要: Graft-mediated antileukemia (GVL) activity is a major factor contributing to the success of allogeneic hematopoietic stem transplantation (aHCT). Recent advances have permitted establishment GVL without need for myeloablative conditioning regimen, thereby permitting even older and sicker patients avail potentially curative therapy. Use adoptive immunotherapy by combining reduced intensity donor leukocyte infusion (DLI) has resulted in strategies that can be exploited maximize effects while minimizing toxicity. These advances, combined with new molecularly targeted agents, creates possibilities develop less toxic, therapy greater number patients. This review summarizes pertinent information regarding evidence favor effects, impact disease type mechanisms GVL.